Thrombus - 2001


Upper limb deep vein thrombosis
Kris Bowles
pp 1-4
Venous thromboembolism can be a painful, disabling and potentially life-threatening condition and most clinicians are familiar with the presentation, investigation and management of venous thrombosis arising in the deep veins of the leg and pelvis. Fewer people will be as familiar with the management and significance of upper limb deep vein thrombosis (ULDVT), which accounts for approximately 2% of all episodes of deep vein thrombosis (DVT) and is becoming increasingly common.
Comment: Examining the links between therapeutic agents and venous thromboembolic disease
Peter Rose
pp 2-2
Patients with inflammatory bowel disease have previously been reported to be at increased risk of venous thromboembolic disease. As with many clinical associations, the evidence to support this one is based on limited reports from case studies or from patients attending specialist inflammatory bowel clinics, where eager medical staff are only too keen to report any possible associations.
The bacterial contamination of platelet products
Barry Hill
pp 5-6
The use of platelet transfusions in British hospitals has dramatically increased over the last decade, primarily as a result of the growing treatment of patients with haematological bleeding disorders. Ever since Duke first demonstrated in 1910 that patients with bleeding due to thrombocytopenia showed marked improvements following transfusions of platelet-rich fresh blood, techniques to prepare and transfuse platelet components have steadily developed.
Thromboembolic disease – time for a review of clinical practice?
Derek Bell
pp 7-8
Pulmonary embolism (PE) is known to be responsible, directly or indirectly, for approximately 18,000 deaths per year in England and Wales, and this figure may, in reality, be higher as clinicians often fail to recognise the condition in life. Both deep vein thrombosis (DVT) and PE are associated with significant levels of morbidity and often require, or contribute to, prolonged hospitalisation. However, thromboembolic disease remains a condition that most doctors feel competent to diagnose and manage, with no single medical specialty taking a clear lead.
The benefits of a Mediterranean diet and statins
Sarah H Wild and Christopher D Byrne
pp 9-11
Various pharmacological and non-pharmacological interventions are effective in both preventing and reducing complications from atherosclerotic vascular disease (AVD). The purpose of this brief review is to discuss some of the recent evidence supporting a beneficial effect for the Mediterranean diet and the statin group of lipid-lowering therapy in reducing risk of AVD.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Group Ltd and, together with the content, is bound by copyright. Copyright © 2018 Hayward Group Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)